Larson C - Search Results

1

A Review of Persistent Post-COVID Syndrome (PPCS).

Oronsky B, Larson C, Hammond TC, Oronsky A, Kesari S, Lybeck M, Reid TR. Oronsky B, et al. Among authors: larson c. Clin Rev Allergy Immunol. 2023 Feb;64(1):66-74. doi: 10.1007/s12016-021-08848-3. Epub 2021 Feb 20. Clin Rev Allergy Immunol. 2023. PMID: 33609255 Free PMC article. Review.

2

Targeting tumors using nanoparticle platforms: a phase I study of a systemically administered gene therapy system.

Larson C, Mendez N, Reid T. Larson C, et al. Mol Ther. 2013 May;21(5):922-3. doi: 10.1038/mt.2013.76. Mol Ther. 2013. PMID: 23636291 Free PMC article. No abstract available.

3

A novel immunocompetent murine model for replicating oncolytic adenoviral therapy.

Zhang L, Hedjran F, Larson C, Perez GL, Reid T. Zhang L, et al. Among authors: larson c. Cancer Gene Ther. 2015 Jan;22(1):17-22. doi: 10.1038/cgt.2014.64. Epub 2014 Dec 19. Cancer Gene Ther. 2015. PMID: 25525035 Free PMC article.

4

Going viral: a review of replication-selective oncolytic adenoviruses.

Larson C, Oronsky B, Scicinski J, Fanger GR, Stirn M, Oronsky A, Reid TR. Larson C, et al. Oncotarget. 2015 Aug 21;6(24):19976-89. doi: 10.18632/oncotarget.5116. Oncotarget. 2015. PMID: 26280277 Free PMC article. Review.

5

Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents.

Oronsky B, Scicinski J, Kim MM, Cabrales P, Salacz ME, Carter CA, Oronsky N, Lybeck H, Lybeck M, Larson C, Reid TR, Oronsky A. Oronsky B, et al. Among authors: larson c. Biomolecules. 2016 Jul 4;6(3):32. doi: 10.3390/biom6030032. Biomolecules. 2016. PMID: 27384589 Free PMC article. Review.

6

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

Oronsky B, Caroen S, Zeman K, Quinn M, Brzezniak C, Scicinski J, Cabrales P, Reid TR, Trepel JB, Abrouk ND, Larson C, Oronsky A, Lybeck HE, Day RM, Carter CA. Oronsky B, et al. Among authors: larson c. Clin Med Insights Oncol. 2016 Nov 6;10:105-108. doi: 10.4137/CMO.S40429. eCollection 2016. Clin Med Insights Oncol. 2016. PMID: 27840583 Free PMC article.

7

Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.

Brzezniak C, Oronsky B, Scicinski J, Caroen S, Cabrales P, Dean Abrouk N, Kim MM, Brown JF, Reid TR, Larson C, Oronsky A, Day R, Degesys A, Carter CA. Brzezniak C, et al. Among authors: larson c. Oncol Res Treat. 2016;39(11):720-723. doi: 10.1159/000449432. Epub 2016 Sep 19. Oncol Res Treat. 2016. PMID: 27855386

8

RRx-001 protects against cisplatin-induced toxicities.

Oronsky B, Reid TR, Larson C, Carter CA, Brzezniak CE, Oronsky A, Cabrales P. Oronsky B, et al. Among authors: larson c. J Cancer Res Clin Oncol. 2017 Sep;143(9):1671-1677. doi: 10.1007/s00432-017-2416-4. Epub 2017 Apr 17. J Cancer Res Clin Oncol. 2017. PMID: 28417195

9

Case Series: Abscopal Benefit of Surgery in 3 Immunotherapy-Treated Patients With Unresectable Cancer.

Oronsky B, Larson C, Reid TR, Carter CA. Oronsky B, et al. Among authors: larson c. J Investig Med High Impact Case Rep. 2018 Jul 6;6:2324709618786319. doi: 10.1177/2324709618786319. eCollection 2018 Jan-Dec. J Investig Med High Impact Case Rep. 2018. PMID: 30083560 Free PMC article.

10

A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs).

Larson C, Oronsky B, Varner G, Caroen S, Burbano E, Insel E, Hedjran F, Carter CA, Reid TR. Larson C, et al. Oncoimmunology. 2018 Jul 23;7(9):e1478648. doi: 10.1080/2162402X.2018.1478648. eCollection 2018. Oncoimmunology. 2018. PMID: 30228948 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,237 results

Search Page